Standard Biotools Inc ( (LAB) ) has released its Q3 earnings. Here is a breakdown of the information Standard Biotools Inc presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Standard BioTools Inc., a prominent player in the biomedical research sector, specializes in providing next-generation technologies such as SomaScan, mass cytometry, and microfluidics to aid researchers in developing better medicines. The company recently reported its financial results for the third quarter of 2025, highlighting a total combined revenue of $46.2 million, with $19.6 million from continuing operations. The company is undergoing a significant restructuring plan aimed at achieving over $40 million in annualized cost savings, setting a path towards positive adjusted EBITDA by 2026.
The third quarter of 2025 saw a decline in revenue from continuing operations by 11% year-over-year, primarily due to reduced project funding in flow and microfluidics, although imaging showed growth. The gross margin also decreased to 48.5% from 54.9% in the previous year. Operating expenses rose by 9% to $42.4 million, influenced by restructuring charges. Despite these challenges, the company maintains a strong cash position with $217 million in cash and cash equivalents, expecting a significant boost from a pending transaction with Illumina.
Standard BioTools is focusing on operational restructuring, which includes a 20% reduction in its global workforce and consolidating operations to increase efficiency. The company plans to relocate its global headquarters to Boston and co-locate its research and development with manufacturing in Singapore. These strategic moves are part of a broader effort to streamline operations and align resources with long-term objectives.
Looking ahead, Standard BioTools remains optimistic about its future, with expectations to achieve profitability in 2026. The anticipated cash infusion from the Illumina transaction is expected to fuel inorganic growth strategies, including mergers and acquisitions, to expand its portfolio and deliver long-term value to shareholders.